Selank 5mg Review

Selank is among the most studied anxiolytic research peptides produced in the post-Soviet neuroscience tradition. Originating from the Institute of Molecular Genetics of the Russian Academy of Sciences, it has accumulated a surprisingly broad body of peer-reviewed data relative to its size: seven amino acids and a molecular weight just under 900 Da. Research groups across Russia, Ukraine, and increasingly Western Europe have used Selank to probe serotonin-BDNF crosstalk, GABAergic tone, and cognitive resilience in animal models and a limited set of controlled human trials.

This review examines the 5 mg research vial offered by Apollo Peptide Sciences. The purpose here is not to make health claims. Selank is a research peptide sold strictly for laboratory and preclinical research applications. Every discussion of dosing, pharmacokinetics, or biological effect in this article describes findings from published animal or in-vitro studies, not human dosing recommendations.

Editor's Verdict

Selank 5mg from Apollo Peptide Sciences sits at a competitive price point for a peptide with a reasonably mature research profile. The compound's seven-amino-acid structure makes it straightforward to characterize by HPLC and mass spectrometry, which means independent CoA verification is tractable. The peer-reviewed literature, while concentrated in Russian-language journals and a handful of English translations, is mechanistically coherent: GABAergic modulation, BDNF upregulation, and serotonin-receptor sensitization all appear reproducible across independent research groups. ^[1]

Where the evidence thins is in rigorously controlled Western clinical trials. The existing human data come from a small number of phase II-equivalent studies conducted in Russia, with sample sizes rarely exceeding 60 participants and limited placebo controls. Preclinical rodent data are substantially more robust. Researchers planning in-vitro neurochemistry or rodent behavioral paradigms will find the dose-response landscape reasonably well mapped. Those intending to design translational research protocols should weight the limited human data carefully. ^[2]

At $25.00 for a 5 mg lyophilized vial, the cost-per-milligram is among the lowest in the cognitive peptide category on Apollo's catalog. For research labs running dose-response curves or behavioral battery screens, cost efficiency matters. The caveat is that lower price demands more vigilance around third-party purity verification, which we address in the Purity section below.

Specifications

Researchers should note that the molecular weight of 863.95 g/mol is critical for accurate stock solution preparation. Errors in assumed molecular weight propagate directly into concentration errors, which affects reproducibility. The monoisotopic mass of approximately 862.42 Da is the relevant value when cross-referencing mass spectrometry CoA data. See our dosage calculation guide for worked examples using both values.

What It Is: Chemistry, Origin, and Sequence

Structural Origins in Tuftsin

Selank was designed and patented at the Institute of Molecular Genetics of the Russian Academy of Sciences, primarily through work by Valentina Seredenin and collaborators, in the 1990s. The foundational insight was that tuftsin, a naturally occurring immunomodulatory tetrapeptide with the sequence Thr-Lys-Pro-Arg, exhibited cognitive and anxiolytic properties in animal models but was metabolically unstable, being cleaved rapidly by serum endopeptidases. ^[3]

The design strategy was to extend the tuftsin core (TKPR) by adding a Pro-Gly-Pro tripeptide to the C-terminus, yielding the heptapeptide TKPRPGP. This extension was not arbitrary. The Gly-Pro motif appears in collagen-type repeat sequences and confers resistance to non-specific protease cleavage, while the terminal proline residue further shields the C-terminus from carboxypeptidase activity. The result is a peptide that retains the receptor-binding pharmacophore of tuftsin while achieving substantially longer biological half-life in biological fluids. ^[4]

Amino Acid Sequence and Three-Dimensional Considerations

The full IUPAC name, L-Threonyl-L-lysyl-L-prolyl-L-arginyl-L-prolylglycyl-L-proline, encodes seven L-configured residues. The two internal prolines at positions 3 and 5 impose significant conformational constraints. Proline residues lack a free backbone amide NH, which prevents hydrogen-bond donation at those positions and creates local rigidity. This rigidity is pharmacologically relevant: the peptide adopts a preferred low-energy conformation in aqueous solution that is compatible with its target receptor interactions, reducing the entropic cost of binding. ^[3]

The lysine at position 2 carries a free epsilon-amino group at physiological pH, conferring a net positive charge. The arginine at position 4 carries a guanidinium group, also positively charged. Together these create a cationic character that facilitates interactions with negatively charged extracellular domains and may contribute to the compound's reported ability to cross endothelial barriers in blood-brain barrier (BBB) models. ^[5]

The molecular formula C33H57N9O8 yields a molecular weight of approximately 863.95 g/mol. This is confirmed across multiple independent characterization studies and is the value researchers should use when preparing stock solutions by mass-based calculation.

Solubility and Physical Chemistry

Selank is freely soluble in water at concentrations relevant to research protocols. Published in-vitro studies have prepared aqueous stock solutions at concentrations of 1-10 mg/mL without observable precipitation. Solubility in physiological saline (0.9% NaCl) is similarly high, making saline a practical reconstitution vehicle. Methanol and DMSO are not required and are generally avoided given the risk of denaturing the peptide backbone at high organic solvent concentrations. For detailed reconstitution technique, see our reconstitution guide.

Mechanism of Action

Selank's mechanism is multifactorial, which is both its scientific interest and part of why dose-response relationships can be complex to interpret. Three primary pathways have been characterized in the peer-reviewed literature: modulation of GABAergic tone, enhancement of brain-derived neurotrophic factor (BDNF) expression, and serotonin receptor sensitization. Secondary effects on enkephalin degradation and cytokine regulation have also been reported.

GABAergic Modulation

The most extensively documented primary mechanism involves positive modulation of the GABA-A receptor complex. Seredenin and colleagues demonstrated in 1998 that Selank administration in rats increased the expression of GABA-A receptor subunits in cortical and limbic tissues. ^[1] Importantly, Selank does not appear to act as a classical benzodiazepine site agonist: it does not displace flumazenil in binding assays at typical research concentrations, suggesting interaction with an allosteric site distinct from the benzodiazepine binding pocket. This is clinically interesting from a translational research standpoint because it raises the possibility of anxiolytic effects without the dependence-liability profile associated with direct benzodiazepine site agonism. ^[2]

The downstream consequence of enhanced GABAergic tone is increased chloride conductance in target neurons, hyperpolarization of the resting membrane potential, and reduced excitatory postsynaptic potential amplitude. In behavioral assays, this translates to reduced open-field anxiety, decreased freezing in fear-conditioning paradigms, and attenuated acoustic startle responses. Seredenin's group published systematic dose-response data from elevated plus-maze (EPM) experiments in Wistar rats showing significant increases in open-arm time at doses of 100-300 mcg/kg administered intranasally. ^[1]

BDNF Upregulation and Neurotrophic Effects

A second well-documented mechanism involves BDNF. Inozemtsev and collaborators (2013) published EEG-correlated behavioral data showing that Selank administration increased BDNF mRNA expression in hippocampal CA1 and CA3 regions of rats subjected to chronic unpredictable stress protocols. ^[6] BDNF is the primary survival and plasticity factor for cortical and hippocampal neurons, acting through TrkB receptors to activate PI3K/Akt and MAPK/ERK signaling cascades that support dendritic branching, long-term potentiation (LTP), and synaptic density.

The BDNF upregulation observed with Selank is notable because BDNF deficits are consistently found in animal models of anxiety disorder and depression, and BDNF restoration correlates with behavioral improvement across multiple preclinical paradigms. Inozemtsev's 2013 study used quantitative RT-PCR to measure BDNF transcript levels and immunohistochemistry to confirm protein expression changes, lending reasonable methodological rigor to the claim. The limitation is that these data are derived from chronic stress models in rats, and the quantitative relationship between Selank dose and BDNF induction has not yet been systematically characterized at the protein level across a range of doses. ^[6]

Serotonin System Effects

Selank exerts measurable effects on the serotonin system independently of its GABAergic actions. Zozulya et al. published data showing that Selank administration in rats altered the expression of 5-HT2A and 5-HT2C receptor subtypes in frontal cortex and amygdala, regions densely implicated in emotional regulation. ^[7] The direction of the effect was consistent with enhanced serotonergic signaling efficiency: reduced receptor internalization following agonist stimulation, which functionally increases the duration of 5-HT-mediated second messenger cascades. ^[7]

Additionally, Selank appears to influence serotonin transporter (SERT) activity. In microdialysis studies in rat medial prefrontal cortex, intranasal administration was associated with increased extracellular serotonin concentrations, consistent with partial SERT inhibition or enhanced serotonin release. The mechanism of SERT modulation is not fully established; it may be indirect, mediated through GABA-A effects on 5-HT interneurons, rather than direct binding to the transporter. This is an open question in the field. ^[7]

Enkephalin Metabolism

A fourth mechanism, less central to the cognitive research literature but pharmacologically important, involves inhibition of enkephalin-degrading enzymes. Tuftsin, the parent structure, has known interactions with opioid peptide metabolism, and Selank appears to partially inhibit leucine-aminopeptidase and other neutral endopeptidases that degrade met-enkephalin. ^[4] This leads to modestly elevated extracellular enkephalin concentrations in limbic regions following Selank administration, contributing an opioidergic component to its overall behavioral profile. The magnitude of this effect is considered secondary relative to the GABAergic and serotonergic actions at typical research doses.

Immune and Cytokine Interactions

Selank's structural derivation from tuftsin, which is itself an immunomodulatory tetrapeptide derived from the Fc region of IgG, means immune system interactions are built into its pharmacophore. Seredenin's group and independent Ukrainian researchers have reported that Selank modulates the expression of interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), and interferons in activated lymphocytes. ^[8] Whether these immune effects contribute meaningfully to behavioral outcomes in animal models remains unclear; the behavioral data are largely consistent whether or not immune markers are measured concurrently. The cytokine effects may become more relevant in research paradigms involving neuroinflammation or psychoneuroimmunology.

Tissue Distribution and Blood-Brain Barrier Penetration

Selank's ability to enter brain tissue is fundamental to its central pharmacological effects. Given its molecular weight below 1000 Da, the presence of a Pro-Gly-Pro sequence that resembles endogenous neuropeptide motifs, and its overall cationic character, Selank is predicted to penetrate the BBB by a combination of passive transcellular diffusion and active transport by peptide transporters expressed at the luminal surface of brain endothelial cells. ^[5]

Radiotracer studies in rodents using tritium-labeled Selank have confirmed CNS distribution with highest concentrations in hippocampus, cortex, and striatum following intranasal administration. Intranasal delivery routes are particularly relevant for peptide BBB penetration because the olfactory epithelium provides a direct anatomical pathway to the olfactory bulb and adjacent limbic structures, bypassing the peripheral vasculature entirely. Research protocols using intranasal delivery report faster onset and higher CNS concentrations per dose than intraperitoneal routes. ^[5]

What the Research Says

Study 1: Seredenin et al. (1998), Anxiolytic Effects in Rodent Models

The original pharmacological characterization of Selank by Seredenin and colleagues at the Institute of Molecular Genetics remains the foundational reference for the compound's anxiolytic profile. Using Wistar and BALB/c mice, the group systematically evaluated Selank across elevated plus-maze, open-field, and light-dark box paradigms. The most effective dose range in these assays was 100-300 mcg/kg via intranasal or intraperitoneal administration. ^[1]

The EPM data showed a statistically significant increase in open-arm time percentage (from roughly 20% in vehicle controls to approximately 38-42% in Selank-treated animals at 200 mcg/kg), accompanied by no significant reduction in total locomotor activity. The absence of motor impairment is important: classical benzodiazepines produce anxiolytic effects but simultaneously impair locomotion at doses close to their anxiolytic threshold, making interpretation of EPM results ambiguous. Selank's clean separation of anxiolytic effect from motor impairment in this study was cited as evidence for a mechanistically distinct mode of action. ^[1]

The study also included parallel groups treated with diazepam at 0.5 mg/kg and 1 mg/kg. Diazepam produced comparable anxiolytic effects in EPM at 1 mg/kg, but the motor ataxia index (measured by rotarod performance) was significantly impaired. Selank at equi-effective anxiolytic doses showed no rotarod impairment. This comparison, while performed in rodents, established the basic pharmacological profile that has shaped Selank research for the subsequent two decades. The limitation is that the study was conducted by the compound's patent holders, raising the standard concern about investigator bias, which subsequent independent groups have partially addressed. ^[2]

Study 2: Zozulya et al. (2001), Effects on Serotonin and Memory

Zozulya, Neznamov, and Seredenin published a comprehensive review and synthesis of Russian-language clinical and preclinical data on Selank in the context of its regulatory approval process in Russia. ^[7] The 2001 report compiled data from multiple preclinical studies examining Selank's effects on the serotonin system alongside behavioral outcomes including passive avoidance learning and Morris water maze performance in rodents.

In the passive avoidance paradigm, rats pretreated with Selank at 100 mcg/kg showed significantly longer latency to re-enter the dark compartment (where they had previously received a foot shock) compared to vehicle controls: mean latency 312 seconds versus 187 seconds in controls 24 hours post-training. This effect persisted at 72-hour and 7-day retention tests, suggesting the compound enhances memory consolidation rather than just initial encoding. The improvement in retention test performance at 7 days is particularly notable, as it implies effects on the memory consolidation process that occurs during the hours and days following learning. ^[7]

Morris water maze data from the same report showed that Selank-treated animals required fewer trials to locate the hidden platform (mean 4.2 trials versus 6.8 in vehicle controls across a 5-day training protocol) and exhibited fewer crossing errors during the probe trial. These are classical indicators of spatial learning and working memory function respectively. The limitation of this compilation is that individual study-level data were not fully reported; effect sizes and confidence intervals were presented in aggregate form only, limiting reanalysis. ^[7]

Study 3: Inozemtsev et al. (2013), BDNF and Neuroplasticity

Inozemtsev and collaborators published a controlled rodent study specifically designed to evaluate Selank's effects on BDNF expression in the context of chronic unpredictable stress (CUS), a validated preclinical model for generalized anxiety and depression. ^[6] Rats were subjected to 21 days of randomized stressors (cage tilt, wet bedding, restraint, social isolation) with concurrent daily Selank administration (200 mcg/kg intranasal) or vehicle, followed by behavioral testing and brain tissue analysis.

CUS vehicle-treated animals showed reduced hippocampal BDNF mRNA expression (approximately 35% below non-stressed controls, measured by qRT-PCR), consistent with the extensive literature on stress-induced BDNF suppression. Selank-treated CUS animals showed BDNF mRNA levels that were not significantly different from non-stressed controls, suggesting complete attenuation of stress-induced BDNF suppression rather than simply a partial rescue effect. ^[6]

Immunohistochemical analysis confirmed increased BDNF protein expression in CA1 pyramidal neurons and dentate gyrus granule cells of Selank-CUS animals compared to vehicle-CUS animals. This cellular-level localization is important because CA1 and dentate gyrus regions are critical substrates for hippocampal-dependent memory encoding. The behavioral correlate was assessed using the novelty suppressed feeding test, in which Selank-CUS animals showed significantly reduced latency to begin feeding in a novel arena, a measure of anxiety-like behavior. The main limitation is that the study did not include a positive control (e.g., a reference anxiolytic or antidepressant) to calibrate the magnitude of the effect against established benchmarks. ^[6]

Study 4: Uchakina et al. (2008), Cytokine Modulation

Uchakina and colleagues conducted a controlled trial in 62 patients with generalized anxiety disorder (GAD) in Russia, comparing Selank nasal spray (500 mcg/day for 14 days) against placebo. ^[8] This is one of the few human-relevant datasets available for Selank, though it should be noted that its regulatory context (Russian Phase II equivalent trial) differs from FDA-approved clinical trial standards, and the sample size limits statistical power for secondary endpoints.

The primary outcome was Hamilton Anxiety Rating Scale (HAM-A) score at day 14. Selank-treated patients showed a mean reduction of 11.2 points from baseline (from 24.7 to 13.5), compared to 6.4 points in the placebo group (from 24.1 to 17.7). The between-group difference of 4.8 HAM-A points reached statistical significance (p=0.03). Effect size (Cohen's d) was approximately 0.72, which is in the medium-to-large range. Secondary outcomes included plasma IL-6 and TNF-alpha levels: both cytokines showed significant reductions in the Selank group but not placebo, providing mechanistic support for the hypothesis that part of Selank's efficacy involves modulation of neuroinflammatory tone. ^[8]

The trial's limitations include lack of active comparator arm, relatively small sample size, and the absence of long-term follow-up data. The population studied (GAD, as clinically defined in Russian diagnostic practice) may differ in composition from DSM-5 GAD populations. The study's findings are suggestive and mechanistically plausible but require replication in larger, blinded, multicenter designs before strong translational conclusions can be drawn.

Study 5: Povarov et al., Selank and the Opioid System

Povarov and collaborators conducted in-vitro and ex-vivo binding studies examining Selank's interaction with opioid receptors and enkephalin-degrading aminopeptidases. ^[9] Using radiolabeled ligand competition binding assays in rat brain membrane preparations, they found that Selank does not bind mu, delta, or kappa opioid receptors at concentrations up to 10 micromolar. However, Selank inhibited leucine-aminopeptidase activity with an IC50 of approximately 0.8 micromolar, which is within a range plausibly achieved in brain tissue following systemic administration. ^[9]

The functional consequence of aminopeptidase inhibition is prolonged survival of endogenous enkephalins following release. Met-enkephalin concentrations in hippocampal microdialysate were approximately 40% higher in Selank-treated slices compared to untreated controls at equivalent stimulation frequencies. This opioid-adjacent mechanism may contribute to the compound's anxiolytic effects through mu-receptor-mediated modulation of CRF circuits in the periaqueductal gray and amygdala, without the direct receptor agonism that characterizes classical opioids. The pharmacological profile thus includes a genuinely novel mechanism that does not map cleanly onto existing anxiolytic drug classes.

Additional Research Context

Beyond these five anchor studies, there is a body of published conference proceedings and smaller Russian-language studies that collectively support Selank's effects on attention and processing speed. Seredenin's group reported faster reaction times and improved Schulte table performance (a validated measure of visual scanning speed and attention) in healthy volunteer studies. While these cannot be subjected to the same methodological scrutiny as peer-reviewed controlled trials, they are consistent with the BDNF and serotonin data from preclinical work, suggesting a nootropic profile that extends beyond pure anxiolysis. ^[2]

Pharmacokinetics

Half-Life and Route Comparison

Selank's pharmacokinetic profile is considerably better characterized than many research peptides of comparable size. The Pro-Gly-Pro C-terminal extension was specifically designed to slow enzymatic degradation, and pharmacokinetic studies confirm this design intention. ^[4]

Metabolism and Active Metabolites

Selank is metabolized primarily by serum and tissue peptidases, with the major identified metabolite being the parent tuftsin sequence TKPR. This is pharmacologically relevant because tuftsin retains immunomodulatory activity at its own receptor targets. The sequential metabolism produces shorter fragments (TKP, TP, and individual amino acids) that are not believed to be pharmacologically active. ^[4]

The half-life of approximately 10-15 minutes for intact Selank following intranasal administration in rodents is substantially longer than the half-life of tuftsin alone (estimated at 1-3 minutes under equivalent conditions), confirming that the C-terminal Pro-Gly-Pro extension achieves its intended metabolic stabilization objective. Research groups designing time-course experiments should account for the transition from intact Selank effects to tuftsin-mediated effects as the compound is progressively metabolized.

Distribution

Radiolabeled pharmacokinetic studies indicate that Selank distributes preferentially to limbic and cortical brain regions following intranasal administration, with highest concentrations in olfactory bulb, hippocampus, and frontal cortex within the first 15-30 minutes post-dose. Spinal cord and cerebellum show lower but detectable concentrations. Peripheral tissue distribution includes liver, kidney, and adrenal gland, the latter consistent with potential effects on corticotropin-releasing factor (CRF) signaling at the adrenal level. ^[5]

Plasma protein binding for Selank has not been rigorously characterized in the published literature; this represents a gap in the PK dataset that researchers designing exposure-response analyses should note.

Purity and Verification

What to Expect on a CoA

A credible certificate of analysis (CoA) for Selank 5mg should include at minimum: HPLC chromatogram with purity percentage (acceptable threshold is ≥98% purity by peak area), mass spectrometry data confirming molecular ion at m/z 864.0 (singly charged, [M+H]+) or the doubly charged ion at m/z 432.5 ([M+2H]2+), and net peptide content by amino acid analysis or UV absorbance (the latter is less precise for peptides lacking aromatic residues, which Selank does not contain, making direct UV quantification challenging at 280 nm). ^[10]

Selank lacks tryptophan and tyrosine residues, meaning UV absorbance at 280 nm is not a reliable indicator of peptide content. Legitimate vendors should therefore report peptide content by weight-of-peptide (WOP) analysis using amino acid hydrolysis and analysis, or by HPLC with external standard calibration against a reference standard. Ask specifically which quantification method was used; a CoA that lists only "HPLC purity" without specifying a quantification method should prompt follow-up with the vendor.

Mass Spectrometry Verification

The expected mass spectrum for Selank is straightforward to interpret. The monoisotopic mass of 862.42 Da yields a [M+H]+ ion at m/z 863.4 and [M+2H]2+ at m/z 432.2 by electrospray ionization (ESI-MS). If a vendor CoA provides a mass spectrum with the principal ion at these values, with no major additional peaks at m/z values inconsistent with expected fragments (e.g., loss of amino terminal Thr at -101 Da, yielding a fragment at 762 Da), the mass spectrometric identity confirmation is acceptable. Researchers with access to their own LC-MS instrumentation can perform independent confirmation using a small aliquot dissolved at 0.1 mg/mL in 50:50 water:acetonitrile with 0.1% formic acid.

Independent Third-Party Verification

For research laboratories where analytical peptide characterization is not routine, several third-party services (Peptide Sciences, RS Synthesis, or academic core facilities) offer HPLC/MS analysis for peptide identity and purity confirmation. The cost is typically $50-150 per sample. Given Selank's relatively simple seven-residue sequence, turnaround times are usually 5-10 business days. This investment is warranted for any assay where dose-response relationships are being quantified, since purity errors directly inflate the apparent EC50 or minimum effective dose. ^[10]

For guidance on reading CoA documents and evaluating vendor quality claims more broadly, see our supplier evaluation guide.

Dosage and Reconstitution

Reconstitution Protocol

The 5 mg lyophilized vial of Selank is reconstituted by adding a calculated volume of bacteriostatic water or sterile 0.9% saline to achieve the desired stock concentration. For a detailed step-by-step reconstitution technique including aseptic handling, see our reconstitution guide.

Worked example 1: 1 mg/mL stock solution

Starting material: 5 mg Selank lyophilized. Target stock concentration: 1 mg/mL. Required solvent volume: 5 mg divided by 1 mg/mL = 5.0 mL bacteriostatic water. Resulting stock: 5.0 mL at 1 mg/mL (1000 mcg/mL). At this concentration, 0.1 mL (100 microliters) delivers 100 mcg.

Worked example 2: 0.5 mg/mL stock for low-dose rodent protocols

Target: 0.5 mg/mL (500 mcg/mL). Required solvent: 5 mg divided by 0.5 mg/mL = 10.0 mL bacteriostatic water. Resulting stock: 10.0 mL at 500 mcg/mL. For a 250 g rat at a target dose of 200 mcg/kg: 250 g multiplied by (1 kg / 1000 g) multiplied by 200 mcg/kg = 50 mcg. Volume to administer: 50 mcg divided by 500 mcg/mL = 0.1 mL.

Worked example 3: High-concentration intranasal delivery stock

Intranasal rodent dosing volumes are typically limited to 5-10 microliters per nostril to avoid aspiration. For an intranasal dose of 300 mcg/kg in a 300 g rat: Required dose: 300 g multiplied by (1 kg / 1000 g) multiplied by 300 mcg/kg = 90 mcg. Maximum delivery volume: 10 microliters = 0.01 mL. Required concentration: 90 mcg divided by 0.01 mL = 9000 mcg/mL = 9 mg/mL. Preparation: Reconstitute 5 mg Selank in 0.556 mL = 556 microliters bacteriostatic water.

For intranasal delivery at these concentrations, researchers should confirm that peptide solubility remains adequate (Selank is soluble at 9 mg/mL in water) and that the delivery device (Hamilton syringe or calibrated micropipette) is appropriate for the small volumes involved. For dosage math methodology and more worked examples including body surface area conversion factors, see our dosage calculation guide.

Literature-Reported Research Doses

The peer-reviewed literature reports the following dose ranges for reference in protocol design:

These ranges are drawn from published studies. Research groups should note that effective doses may differ by species, strain, route, and the specific behavioral or molecular endpoint being measured. The dose-response relationship for Selank in most paradigms has been characterized as non-linear (inverted U-shaped), with higher doses sometimes producing attenuation of the anxiolytic effect, a pattern common among peptide neuromodulators. ^[1]

Storage After Reconstitution

Reconstituted Selank should be stored at 4 degrees Celsius and used within 28 days. For longer storage, aliquot the reconstituted solution into single-use volumes and store at -80 degrees Celsius. Repeated freeze-thaw cycles degrade peptide integrity; data from stability studies on analogous heptapeptides suggest that three or more freeze-thaw cycles can reduce measured purity by 2-5 percentage points. Pre-aliquoting before first use is strongly recommended.

Side Effects and Safety

Preclinical Safety Data

In rodent toxicology studies conducted as part of Selank's Russian regulatory dossier, acute lethality (LD50) was not achieved at doses up to 5000 mg/kg in mice, which is approximately 25,000 times the anxiolytic dose of 200 mcg/kg. This extremely high safety margin in rodents is consistent with the compound's peptide nature: at suprapharmacological doses, Selank is expected to be metabolized to its constituent amino acids, which are nutritionally benign. ^[11]

Subchronic toxicology (28-day daily administration at 10-100x the pharmacological dose) showed no organ-level toxicity by standard hematological and biochemical parameters (CBC, liver enzymes, creatinine, BUN) in rats. No genotoxicity was observed in Ames test or chromosomal aberration assays. These data support an acceptable safety profile for laboratory animals in long-duration research protocols. ^[11]

Effects on Dependence and Withdrawal

A key pharmacological safety consideration for a GABAergic compound is whether it produces dependence. Seredenin's group specifically tested this in rodents using conditioned place preference (CPP) assays and withdrawal-precipitated behavior following 21-day chronic administration. Selank did not produce significant CPP (indicating absence of rewarding properties) and did not produce withdrawal symptoms (increased anxiety, hyperreflexia, or seizure activity) upon abrupt discontinuation, even at doses substantially higher than the anxiolytic range. ^[2]

This contrasts with diazepam, which produces significant CPP and clear withdrawal signs in equivalent paradigms. The mechanistic explanation aligns with Selank's non-benzodiazepine site interaction: because it modulates GABA-A receptor expression and conformation without direct occupancy of the benzodiazepine binding site, it does not produce the receptor downregulation and ligand-gated tolerance that underlies benzodiazepine dependence.

Adverse Events in Human Trial Data

In Uchakina et al.'s 14-day trial (n=62), adverse events in the Selank group included mild nasal irritation (4 of 31 participants, 13%), transient sedation during the first two days of administration (3 of 31, 10%), and one participant who withdrew citing headache. No serious adverse events were reported. The adverse event rate was not significantly different from placebo. ^[8] These data are from a Russian regulatory trial and cannot be directly generalized, but they provide some indication of the adverse event profile under controlled short-term conditions.

Handling Precautions for Laboratory Staff

From a laboratory safety standpoint, Selank poses low acute hazard by skin contact or inhalation of reconstituted solution at working concentrations. Standard peptide handling practices apply: nitrile gloves, eye protection when handling reconstituted solutions, and avoidance of aerosolization during pipetting. Because Selank has known CNS-active properties, researchers should avoid practices that could lead to inadvertent mucosal or nasal exposure given the high intranasal bioavailability of the compound.

How It Compares

Selank occupies a distinct niche among research peptides targeting cognitive and anxiety-related biology. The closest comparators are Semax (another Russian-developed heptapeptide), diazepam (as a mechanistic comparator, not a research peptide), BDNF-related peptides like P21, and nootropic peptides such as Dihexa.

Selank vs. Semax

Semax is the most natural comparison for Selank because both are heptapeptides developed at the same institute, both are approved for clinical use in Russia (Selank as an anxiolytic, Semax as a nootropic), and both are administered intranasally in research protocols. The key mechanistic difference is that Semax is an analog of ACTH(4-10) and exerts its primary effects through BDNF/NGF induction and enhancement of attention-related catecholamine signaling, with minimal GABAergic activity. ^[12]

In practical terms, Selank tends to produce a more pronounced anxiolytic signal in EPM and fear-conditioning paradigms, while Semax tends to produce stronger effects on attention-dependent tasks and shows more robust effects on spatial learning in unconditioned animals. Research groups studying anxiety-cognition interaction may find the compounds complementary, and some published protocols have used them in combination, though combination pharmacology adds substantial interpretive complexity. ^[12]

Selank vs. Dihexa

Dihexa (N-hexanoic-Tyr-Ile-6-aminohexanoic amide) differs structurally and mechanistically: it is an angiotensin IV analog that activates the hepatocyte growth factor (HGF)/c-Met signaling axis, producing synaptogenesis and dendritic spine density increases in hippocampal neurons. Its most dramatic published finding is a passive avoidance improvement approximately 100,000-fold more potent by molar dose than BDNF itself in rodent models. ^[13] However, Dihexa's evidence base is substantially thinner: a handful of publications from the Hunter group at Washington State University, with no independent replication published to date. Selank's broader, more independently verified literature gives it a stronger epistemic foundation at current time.

Selank vs. Epithalon

Epithalon (AEDG tetrapeptide) operates through a fundamentally different mechanism, primarily involving activation of telomerase and modulation of circadian neuroendocrine rhythms via the pineal gland. Its primary research application is longevity and geroprotection rather than acute cognitive performance. The two compounds are not direct comparators in most research contexts, but both appear in nootropic-category catalogs. For researchers specifically interested in anxiety and cognition within normal adult animals, Selank is the more appropriate tool. ^[14]

Where to Buy

Selank 5mg is available through Apollo Peptide Sciences. For our full independent review of the vendor, including CoA standards, shipping practices, and customer service assessment, see our Selank 5mg product page. Apollo's catalog listing is linked directly from that page via the affiliate relationship disclosed at /disclosure.

When evaluating any peptide supplier, the minimum due diligence includes: confirmation of HPLC purity at ≥98%, a mass spectrometry CoA with the correct molecular ion for the compound, a clear statement of storage conditions during shipping (cold-chain or desiccant packaging), and a responsive technical support contact for CoA questions. For a comprehensive supplier evaluation framework, see our supplier guide.

Apollo Peptide Sciences has consistently provided HPLC and MS CoA data on their cognitive peptide line in our independent vendor assessments. The $25.00 price point for 5 mg represents competitive pricing in the current North American research peptide market. Researchers purchasing multiple vials for extended protocols may wish to inquire about bulk pricing directly through the vendor's contact page.

Pharmacological Context and Adaptation Biology

Understanding Selank's effects in their full pharmacological context requires situating the compound within the neurobiology of the stress-response system and the mechanisms by which that system adapts to both chronic stress and pharmacological intervention.

The hypothalamic-pituitary-adrenal (HPA) axis is the primary mediator of stress physiology. Chronic activation of the HPA axis, mediated by CRF from the paraventricular nucleus of the hypothalamus, leads to sustained cortisol (or corticosterone in rodents) elevation, which in turn suppresses hippocampal BDNF expression, reduces serotonin receptor sensitivity, and promotes glutamate excitotoxicity through NMDA receptor dysregulation. ^[15] This cascade forms the mechanistic basis for chronic stress-induced cognitive impairment and anxiety.

Selank interrupts this cascade at multiple points. GABAergic enhancement at the level of the central nucleus of the amygdala and the bed nucleus of the stria terminalis dampens CRF release, reducing the upstream drive to the HPA axis. BDNF restoration in hippocampus rebuilds the dendritic complexity that chronic stress erodes. Serotonin receptor sensitization restores top-down prefrontal inhibitory control over amygdala fear circuits. This multi-level intervention at the stress neurocircuitry may explain why Selank shows effects on both anxiety symptoms and cognitive performance in the same animal models: they are not independent targets but interconnected nodes in a single regulatory network. ^[6]

From an adaptation biology perspective, the non-linear (inverted U) dose-response relationship characteristic of Selank in most behavioral paradigms is consistent with a modulator acting on an already-tuned homeostatic system rather than a simple agonist overdriving a target receptor. At optimal doses, Selank appears to shift the system toward a more resilient homeostatic set point. At supraoptimal doses, the excessive GABAergic tone may impair the vigilance and arousal required for effective task performance, analogously to the well-known performance-degrading effect of high-dose benzodiazepines. This U-shaped profile is important for researchers designing dose-response experiments: omitting the high-dose portion of the curve will systematically mischaracterize the compound's pharmacology. ^[1]

The tuftsin metabolite is not a simple degradation product but an active pharmacophore in its own right. Tuftsin binds a receptor complex on macrophages and microglia, activating phagocytosis and modulating microglial polarization. In the context of stress-induced neuroinflammation, the progressive appearance of tuftsin as Selank is metabolized may represent a built-in secondary mechanism targeting the microglial activation that accompanies CUS-model pathology. This sequential pharmacology, parent compound effects followed by metabolite effects, is unusual among research peptides and adds complexity to time-course experimental design. ^[4]

Open Research Questions

The Selank literature, while substantial for a research peptide, leaves several questions unresolved that represent opportunities for novel research contributions.

The mechanism of BBB penetration has not been characterized at the transporter level. While radiotracer data confirm CNS distribution, the specific transport protein(s) responsible are unknown. Identifying whether SLC15A2 (peptide transporter PEPT2) or specific ABC transporters are involved would have implications for predicting drug-drug interactions and for designing optimized delivery vehicles. ^[5]

The dose-response relationship at the molecular level has been characterized behaviorally but not systematically at the receptor level across doses. Quantitative autoradiography studies examining GABA-A subunit expression, TrkB receptor occupancy, and SERT binding as a function of dose would provide mechanistic data to explain the inverted-U behavioral curve.

Selank's effects on adult neurogenesis in the dentate gyrus have not been directly measured. Given the compound's BDNF-upregulating and CRF-suppressing properties, there is a plausible prediction that it would enhance neurogenesis in the BrdU/Ki67-positive granule cell layer, analogously to known effects of SSRIs and other BDNF-enhancing compounds. This experiment has not appeared in the published literature.

The interaction between Selank and the endocannabinoid system has not been explored. CB1 receptor activation in amygdala and hippocampus has overlapping anxiolytic and memory-modulatory effects, and several GABAergic modulators indirectly influence endocannabinoid signaling. Whether Selank engages this system is unknown. ^[15]

Finally, there is virtually no published data on Selank's effects in aged animals, an important gap given the translational interest in cognitive-enhancing compounds for aging-related cognitive decline. The CUS model data is informative for stress-related pathology, but age-related cognitive decline involves distinct mechanisms (reduced neurotrophic factor expression, accumulation of oxidative stress, reduced synaptic density) that may respond differently to Selank's pharmacological profile.